Natural products as Anti-HIV agents and role in HIV-associated neurocognitive disorders (HAND): A brief overview

Frontiers in Microbiology

Volumn 6, Issue JAN, 2016, Pages

  Kurapati, Kesava Rao V ^a   Atluri, Venkata S ^a   Samikkannu, Thangavel ^a   Garcia, Gabriella ^a   Nair, Madhavan P N ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Anti HIV agents; HIV; Natural products; Neurocognitive disorders

Indexed keywords

ALKALOID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BAICALIN; BETULIC ACID; BIFLAVONOID; CALANOLIDE; CALANOLIDE B; CATECHOL; CHEBULAGIC ACID; COUMARIN; FLAVONOID; GALLIC ACID; HYPOGLAUMINE B; LIGNAN DERIVATIVE; LITHOSPERMIC ACID; NITIDINE; PAPAVERINE; PELTATOL A; PLANT EXTRACT; POLYCITONE A; PUNICALAGIN; PUNICALIN; QUINONE DERIVATIVE; SAPONIN; TERPENE DERIVATIVE; TROPONINE A; TROPONINE B; UNCLASSIFIED DRUG; UNINDEXED DRUG; WITHANIA SOMNIFERA EXTRACT; XANTHONE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIODIVERSITY; CELLULAR DISTRIBUTION; COGNITION; DNA INTEGRATION; DRUG BIOAVAILABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; LONG TERMINAL REPEAT; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; REVERSE TRANSCRIPTION; REVIEW; RISK ASSESSMENT; VIRUS ENTRY; VIRUS REPLICATION;

EID: 84957998998     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.01444     Document Type: Review

References (184)

1. Abd-Elazem, I. S., Chen, H. S., Bates, R. B., and Huang, R. C. (2002). Isolation of two highly potent and non-toxic inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase from Salvia miltiorrhiza. Antiviral Res. 55, 91-106. doi: 10.1016/S0166-3542(02)00011-6.
2. Achim, C. L., and Wiley, C. A. (1996). Inflammation in AIDS and the role of the macrophage in brain pathology. Curr. Opin. Neurol. 9, 221-225. doi: 10.1097/00019052-199606000-00013.
3. Ahn, M.-J., Kim, C. Y., Lee, J. S., Kim, T. G., Kim, S. H., Lee, C.-K., et al. (2002). Inhibition of HIV-1 integrase by galloyl glucoses from terminalia chebula and flavonol glycoside gallates from Euphorbia pekinensis. Planta Med. 68, 457-459. doi: 10.1055/s-2002-32070.
4. An, P., Bleiber, G., Duggal, P., Nelson, G., May, M., Mangeat, B., et al. (2004). APOBEC3G genetic variants and their influence on the progression to AIDS. J. Virol. 78, 11070-11076. doi: 10.1128/jvi.78.20.11070-11076.2004.
5. Anthony, I., Ramage, S., Carnie, F., Simmonds, P., and Bell, J. (2006). Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol. 111, 529-538. doi: 10.1007/s00401-006-0037-0.
6. Anthony, I. C., and Bell, J. E. (2008). The neuropathology of HIV/AIDS. Int. Rev. Psychiatry 20, 15-24. doi: 10.1080/09540260701862037.
7. Antinori, A., Arendt, G., Becker, J. T., Brew, B. J., Byrd, D. A., Cherner, M., et al. (2007). Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69, 1789-1799. doi: 10.1212/01.WNL.0000287431.88658.8b.
8. Appay, V., Almeida, J. R., Sauce, D., Autran, B., and Papagno, L. (2007). Accelerated immune senescence and HIV-1 infection. Exp. Gerontol. 42, 432-437. doi: 10.1016/j.exger.2006.12.003.
9. Asres, K., Bucar, F., Kartnig, T., Witvrouw, M., Pannecouque, C., and De Clercq, E. (2001). Antiviral activity against human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) of ethnobotanically selected Ethiopian medicinal plants. Phytother. Res. 15, 62-69. doi: 10.1002/1099-1573(200102)15:1<62::AID-PTR956>3.0.CO;2-X.
10. Atluri, V. S., Hidalgo, M., Samikkannu, T., Kurapati, K. R., Jayant, R. D., Sagar, V., et al. (2015). Effect of human immunodeficiency virus on blood-brain barrier integrity and function: an update. Front. Cell Neurosci. 9:212. doi: 10.3389/fncel.2015.00212.
11. Atluri, V. S., Pilakka-Kanthikeel, S., Samikkannu, T., Sagar, V., Kurapati, K. R., Saxena, S. K., et al. (2014). Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder. Mol. Brain 7:37. doi: 10.1186/1756-6606-7-37.
12. Balzarini, J. (1994). Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm. World Sci. 16, 113-126. doi: 10.1007/BF01880662.
13. Benito, J. M., Lopez, M., and Soriano, V. (2004). The role of CD8+ T-cell response in HIV infection. AIDS Rev. 6, 79-88.
14. Beutler, J. A., Cardellina, J. H., Mcmahon, J. B., Boyd, M. R., and Cragg, G. M. (1992). Anti-HIV and cytotoxic alkaloids from Buchenavia capitata. J. Nat. Prod. 55, 207-213. doi: 10.1021/np50080a008.
15. Brandt, J., Butters, N., Ryan, C., and Bayog, R. (1983). Cognitive loss and recovery in long-term alcohol abusers. Arch. Gen. Psychiatry 40, 435-442. doi: 10.1001/archpsyc.1983.01790040089012.
16. Broder, S. (2009). The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 85, 1-18. doi: 10.1016/j.antiviral.2009.10.002.
17. Buonaguro, L., Tornesello, M. L., and Buonaguro, F. M. (2007). Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J. Virol. 81, 10209-10219. doi: 10.1128/JVI.00872-07.
18. Chan, D. C., and Kim, P. S. (1998). HIV entry and its inhibition. Cell 93, 681-684. doi: 10.1016/S0092-8674(00)81430-0.
19. Chang, L., Ernst, T., Witt, M. D., Ames, N., Gaiefsky, M., and Miller, E. (2002). Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-Naïve HIV patients. NeuroImage 17, 1638-1648. doi: 10.1006/nimg.2002.1254.
20. Charlton, J. L. (1998). Antiviral activity of lignans. J. Nat. Prod. 61, 1447-1451. doi: 10.1021/np980136znp980136z.
21. Chen, D.-F., Zhang, S.-X., Wang, H.-K., Zhang, S.-Y., Sun, Q.-Z., Cosentino, L. M., et al. (1999). Novel anti-HIV lancilactone C and related triterpenes from Kadsura lancilimba. J. Nat. Prod. 62, 94-97. doi: 10.1021/np980291d.
22. Chen, D. F., Zhang, S. X., Xie, L., Xie, J. X., Chen, K., Kashiwada, Y., et al. (1997). Anti-AIDS agents-XXVI. Structure-activity correlations of gomisin-G-related anti-HIV lignans from Kadsura interior and of related synthetic analogues. Bioorg. Med. Chem. 5, 1715-1723. doi: 10.1016/S0968-0896(97)00118-1.
23. Chinsembu, K., and Hedimbi, M. (2010). Ethnomedicinal plants and other natural products with anti-HIV active compounds and their putative modes of action. Int. J. Biotechnol. Mol. Biol. Res. 1, 74-91.
24. Clerici, M., Balotta, C., Salvaggio, A., Riva, C., Trabattoni, D., Papagno, L., et al. (1996). Human immunodeficiency virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood 88, 574-579.
25. Cohen, J. (2012). The many states of HIV in America. Science 337, 168-171. doi: 10.1126/science.337.6091.168.
26. Creagh, T., Ruckle, J. L., Tolbert, D. T., Giltner, J., Eiznhamer, D. A., Dutta, B., et al. (2001). Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob. Agents Chemother. 45, 1379-1386. doi: 10.1128/AAC.45.5.1379-1386.2001.
27. Darbinian-Sarkissian, N., Darbinyan, A., Otte, J., Radhakrishnan, S., Sawaya, B. E., Arzumanyan, A., et al. (2006). p27(SJ), a novel protein in St John's Wort, that suppresses expression of HIV-1 genome. Gene Ther. 13, 288-295. doi: 10.1038/sj.gt.3302649.
28. Darke, S., Sims, J., Mcdonald, S., and Wickes, W. (2000). Cognitive impairment among methadone maintenance patients. Addiction 95, 687-695. doi: 10.1046/j.1360-0443.2000.9556874.x.
29. De Clercq, E. (1995). Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8, 200-239.
30. Decosterd, L. A., Parsons, I. C., Gustafson, K. R., Cardellina, J. H., Mcmahon, J. B., Cragg, G. M., et al. (1993). HIV inhibitory natural products. 11. Structure, absolute stereochemistry, and synthesis of conocurvone, a potent, novel HIV-inhibitory naphthoquinone trimer from a Conospermum sp. J. Am. Chem. Soc. 115, 6673-6679. doi: 10.1021/ja00068a026.
31. de Oliveira, T., Pillay, D., Gifford, R. J., and UK Collaborative Group on Hiv Drug Resistance (2010). The HIV-1 subtype c epidemic in South America is linked to the United Kingdom. PLoS ONE 5:e9311. doi: 10.1371/journal.pone.0009311.
32. Devlin, K. N., Gongvatana, A., Clark, U. S., Chasman, J. D., Westbrook, M. L., Tashima, K. T., et al. (2012). Neurocognitive effects of HIV, hepatitis C, and substance use history. J. Int. Neuropsychol. Soc. 18, 68-78. doi: 10.1017/s1355617711001408.
33. Dharmaratne, H. R. W., Tan, G. T., Marasinghe, G. P. K., and Pezzuto, J. M. (2002). Inhibition of HIV-1 reverse transcriptase and HIV-1 replication by Calophyllum coumarins and Xanthones. Planta Med. 68, 86-87. doi: 10.1055/s-2002-20058.
34. Dhillon, N., Williams, R., Peng, F., Tsai, Y.-J., Dhillon, S., Nicolay, B., et al. (2007). Cocaine-mediated enhancement of virus replication in macrophages: implications for human immunodeficiency virus-associated dementia. J. Neurovirol. 13, 483-495. doi: 10.1080/13550280701528684.
35. Duan, H., Takaishi, Y., Imakura, Y., Jia, Y., Li, D., Cosentino, L. M., et al. (2000). Sesquiterpene alkaloids from Tripterygium hypoglaucum and Tripterygium wilfordii: a new class of potent Anti-HIV agents. J. Nat. Prod. 63, 357-361. doi: 10.1021/np990281s.
36. Ellis, R. J., Badiee, J., Vaida, F., Letendre, S., Heaton, R. K., Clifford, D., et al. (2011). CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25, 1747-1751.
37. El-Mekkawy, S., Meselhy, M. R., Nakamura, N., Hattori, M., Kawahata, T., and Otake, T. (2000). Anti-HIV-1 phorbol esters from the seeds of Croton tiglium. Phytochemistry 53, 457-464. doi: 10.1016/S0031-9422(99)00556-7.
38. Esiri, M. M., Biddolph, S. C., and Morris, C. S. (1998). Prevalence of alzheimer plaques in AIDS. J. Neurol. Neurosurg. Psychiatry 65, 29-33. doi: 10.1136/jnnp.65.1.29.
39. Ettenhofer, M. L., Hinkin, C. H., Castellon, S. A., Durvasula, R., Ullman, J., Lam, M., et al. (2009). Aging, neurocognition, and medication adherence in HIV infection. Am. J. Geriatr. Psychiatry 17, 281-290. doi: 10.1097/JGP.0b013e31819431bd00019442-200904000-00004.
40. Fabricant, D. S., and Farnsworth, N. R. (2001). The value of plants used in traditional medicine for drug discovery. Environ. Health Perspect. 109, 69-75. doi: 10.2307/3434847.
41. Farnsworth, N. R. (2007). "Ethnopharmacology and drug development," in Ciba Foundation Symposium 185-Ethnobotany and the Search for New Drugs, eds D. J. Chadwick and J. Marsh (Hoboken, NJ: John Wiley & Sons, Ltd), 42-59.
42. Fuller, R. W., Westergaard, C. K., Collins, J. W., Cardellina, J. H., and Boyd, M. R. (1999). Vismiaphenones D-G, new prenylated benzophenones from Vismia cayennensis. J. Nat. Prod. 62, 67-69. doi: 10.1021/np980152w.
43. Fundacio Lluita Contra la SIDA (2011). Clinicaltrials.gov, 'Drug Interactions Between Echinacea Purpurea and Etravirine'. Available at: Clinicaltrials.gov [accessed December 1, 2015].
44. Futterman, D. (2012). HIV/AIDS: the next generation. Science 337:799. doi: 10.1126/science.337.6096.799-a.
45. Gandhi, N., Saiyed, Z., Napuri, J., Samikkannu, T., Reddy, P. B., Agudelo, M., et al. (2010). Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder. J. Neurovirol. 16, 294-305. doi: 10.3109/13550284.2010.499891.
46. Gandhi, N., Saiyed, Z., Thangavel, S., Rodriguez, J., Rao, K. V. K., and Nair, M. P. N. (2009). Differential effects of HIV type 1 clade B and clade C tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes. AIDS Res. Hum. Retrovir. 25, 691-699. doi: 10.1089/aid.2008.0299.
47. Gannon, P., Khan, M. Z., and Kolson, D. L. (2013). Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr. Opin. Neurol. 24, 275-283. doi: 10.1097/WCO.0b013e32834695fb.
48. Giunta, B., Ehrhart, J., Obregon, D. F., Lam, L., Le, L., Jin, J., et al. (2011). Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. Mol. Brain 4, 23-23. doi: 10.1186/1756-6606-4-23.
49. Gonzalez, R., Heaton, R. K., Moore, D. J., Letendre, S., Ellis, R. J., Wolfson, T., et al. (2003). Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J. Int. Neuropsychol. Soc. 9, 64-71. doi: 10.1017/S1355617703910071.
50. Gonzalez-Scarano, F., and Martin-Garcia, J. (2005). The neuropathogenesis of AIDS. Nat. Rev. Immunol. 5, 69-81. doi: 10.1038/nri1527.
51. Green, D. A., Masliah, E., Vinters, H. V., Beizai, P., Moore, D. J., and Achim, C. L. (2005). Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19, 407-411. doi: 10.1097/01.aids.0000161770.06158.5c.
52. Grovit-Ferbas, K., and Harris-White, M. E. (2010). Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction. Immunol. Res. 48, 40-58. doi: 10.1007/s12026-010-8166-x.
53. Groweiss, A., Cardellina, J. H., and Boyd, M. R. (2000). HIV-Inhibitory prenylated Xanthones and flavones from Maclura tinctoria. J. Nat. Prod. 63, 1537-1539. doi: 10.1021/np000175m.
54. Gustafson, K. R., Cardellina, J. H., Mcmahon, J. B., Pannell, L. K., Cragg, G. M., and Boyd, M. R. (1992). HIV inhibitory natural products. 6. The peltatols, novel HIV-inhibitory catechol derivatives from Pothomorphe peltata. J. Organ. Chem. 57, 2809-2811. doi: 10.1021/jo00036a010.
55. Heaton, R. K., Clifford, D. B., Franklin, D.R. Jr, Woods, S. P., Ake, C., Vaida, F., et al. (2010). HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75, 2087-2096. doi: 10.1212/WNL.0b013e318200d727.
56. Heaton, R. K., Franklin, D. R., Ellis, R. J., Mccutchan, J. A., Letendre, S. L., Leblanc, S., et al. (2011). HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J. Neurovirol. 17, 3-16. doi: 10.1007/s13365-010-0006-1.
57. Hedimbi, M., and Chinsembu, K. C. (2012). Ethnomedicinal study of plants used to manage HIV/AIDS-related disease conditions in the Ohangwena region, Namibia. Int. J. Med. Plants Res. 1, 4-11.
58. Hemelaar, J. (2012). The origin and diversity of the HIV-1 pandemic. Trends Mol. Med. 18, 182-192. doi: 10.1016/j.molmed.2011.12.001.
59. Hemelaar, J., Gouws, E., Ghys, P. D., and Osmanov, S. (2011). Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25, 679-689. doi: 10.1097/QAD.0b013e328342ff93.
60. Hidalgo, M., Atluri, V. S. R., and Nair, M. (2015). Drugs of abuse in HIV infection and neurotoxicity. Front. Microbiol. 6:217. doi: 10.3389/fmicb.2015.00217.
61. Honig, L. S., Schupf, N., Lee, J. H., Tang, M. X., and Mayeux, R. (2006). Shorter telomeres are associated with mortality in those with APOE ε4 and dementia. Ann. Neurol. 60, 181-187. doi: 10.1002/ana.20894.
62. Hu, K., Kobayashi, H., Dong, A., Iwasaki, S., and Yao, X. (2000). Antifungal, antimitotic and anti-HIV-1 agents from the roots of Wikstroemia indica. Planta Med. 66, 564-567. doi: 10.1055/s-2000-8601.
63. Ishida, J., Wang, H.-K., Oyama, M., Cosentino, M. L., Hu, C.-Q., and Lee, K.-H. (2001). Anti-AIDS agents. 46.1 anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its Derivatives. J. Nat. Prod. 64, 958-960. doi: 10.1021/np0101189.
64. Jaco, H., King, R. L., Tenywa, T., Kyeyune, P., and Opio, A. (2004). Defining minimum standards of practice for incorporating african traditional medicine into HIV/AIDS prevention, care, and support: a regional initiative in eastern and Southern Africa. J. Altern. Complement. Med. 10, 905-910. doi: 10.1089/acm.2004.10.905.
65. Jiang, S., Zhao, Q., and Debnath, A. K. (2002). Peptide and non-peptide HIV fusion inhibitors. Curr. Pharm. Des. 8, 563-580. doi: 10.2174/1381612024607180.
66. Jain, S., Shukla, S. D., Sharma, K., and Bhatnagar, M. (2001). Neuroprotective effects of Withania somnifera Dunn. in hippocampal sub-regions of female albino rat. Phytother. Res. 15, 544-548. doi: 10.1002/ptr.802.
67. Kashiwada, Y., Nishizawa, M., Yamagishi, T., Tanaka, T., Nonaka, G.-I., Cosentino, L. M., et al. (1995). Anti-AIDS Agents, 18. sodium and potassium salts of caffeic acid tetramers from Arnebia euchroma as anti-HIV agents. J. Nat. Prod. 58, 392-400. doi: 10.1021/np50117a007.
68. Kashiwada, Y., Wang, H.-K., Nagao, T., Kitanaka, S., Yasuda, I., Fujioka, T., et al. (1998). Anti-AIDS agents. 30. anti-HIV activity of oleanolic acid, pomolic acid, and structurally related triterpenoids. J. Nat. Prod. 61, 1090-1095. doi: 10.1021/np9800710.
69. Kaul, M. (2009). HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr. Opin. Neurol. 22, 315-320. doi: 10.1097/WCO.0b013e328329cf3c.
70. Kaul, M., Garden, G. A., and Lipton, S. A. (2001). Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410, 988-994. doi: 10.1038/3507366735073667.
71. Kaul, M., and Lipton, S. A. (2006). Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. J. Neuroimmune Pharmacol. 1, 138-151. doi: 10.1007/s11481-006-9011-9.
72. Kim, H. J., Woo, E.-R., Shin, C.-G., and Park, H. (1998). A new flavonol glycoside gallate ester from Acer okamotoanum and its inhibitory activity against human immunodeficiency virus-1 (HIV-1) integrase. J. Nat. Prod. 61, 145-148. doi: 10.1021/np970171q.
73. Kim, S. R., Jeong, H. Y., Yang, S., Choi, S. P., Seo, M. Y., Yun, Y. K., et al. (2011). Effects of chronic alcohol consumption on expression levels of APP and abeta-producing enzymes. BMB Rep. 44, 135-139. doi: 10.5483/BMBRep.2011.44.2.135.
74. Kitamura, K., Honda, M., Yoshizaki, H., Yamamoto, S., Nakane, H., Fukushima, M., et al. (1998). Baicalin, an inhibitor of HIV-1 production in vitro. Antiviral Res. 37, 131-140. doi: 10.1016/S0166-3542(97)00069-7.
75. Kitchen, C. M., Kitchen, S. G., Dubin, J. A., and Gottlieb, M. S. (2001). Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. Clin. Infect. Dis. 33, 466-472. doi: 10.1086/321900.
76. Klos, M., Van De Venter, M., Milne, P. J., Traore, H. N., Meyer, D., and Oosthuizen, V. (2009). In vitro anti-HIV activity of five selected South African medicinal plant extracts. J. Ethnopharmacol. 124, 182-188. doi: 10.1016/j.jep.2009.04.043.
77. Kraft-Terry, S. D., Buch, S. J., Fox, H. S., and Gendelman, H. E. (2009). A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron 64, 133-145. doi: 10.1016/j.neuron.2009.09.042.
78. Kuboyama, T., Tohda, C., and Komatsu, K. (2005). Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br. J. Pharmacol. 144, 961-971. doi: 10.1038/sj.bjp.0706122.
79. Kulkarni, S. K., and Dhir, A. (2008). Withania somnifera: an Indian ginseng. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1093-1105. doi: 10.1016/j.pnpbp.2007.09.011.
80. Kumari, G., and Singh, R. K. (2012). Highly active antiretroviral therapy for treatment of HIV/AIDS patients: current status and future prospects and the Indian scenario. HIV AIDS Rev. 11, 5-14. doi: 10.1016/j.hivar.2012.02.003.
81. Kurapati, K. R., Atluri, V. S., Samikkannu, T., and Nair, M. P. (2013). Ashwagandha (Withania somnifera) reverses beta-amyloid1-42 induced toxicity in human neuronal cells: implications in HIV-associated neurocognitive disorders (HAND). PLoS ONE 8:e77624. doi: 10.1371/journal.pone.0077624PONE-D-13-22227.
82. Kurapati, K. R., Samikkannu, T., Atluri, V. S., Kaftanovskaya, E., Yndart, A., and Nair, M. P. (2014). beta-Amyloid1-42, HIV-1Ba-L (clade B) infection and drugs of abuse induced degeneration in human neuronal cells and protective effects of ashwagandha (Withania somnifera) and its constituent Withanolide A. PLoS ONE 9:e112818. doi: 10.1371/journal.pone.0112818PONE-D-14-30964.
83. Lawn, S. D., Butera, S. T., and Folks, T. M. (2001). Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin. Microbiol. Rev. 14, 753-777. doi: 10.1128/CMR.14.4.753-777.2001.
84. Lee, T. T.-Y., Kashiwada, Y., Huang, L., Snider, J., Cosentino, M., and Lee, K.-H. (1994). Suksdorfin: an anti-HIV principle from Lomatium suksdorfii, its structure-activity correlation with related coumarins, and synergistic effects with anti-AIDS nucleosides. Bioorg. Med. Chem. 2, 1051-1056. doi: 10.1016/S0968-0896(00)82054-4.
85. Lee-Huang, S., Huang, P. L., Huang, P. L., Bourinbaiar, A. S., Chen, H. C., and Kung, H. F. (1995). Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31. Proc. Natl. Acad. Sci. U.S.A. 92, 8818-8822.
86. Li, H.-Y., Sun, N.-J., Kashiwada, Y., Sun, L., Snider, J. V., Cosentino, L. M., et al. (1993). Anti-AIDS agents, 9. Suberosol, a new C31 lanostane-type triterpene and Anti-HIV principle from Polyalthia suberosa. J. Nat. Prod. 56, 1130-1133. doi: 10.1021/np50097a017.
87. Li, T. (2014). Clinicaltrials.gov, 'Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection'. Available at: Clinicaltrials.gov [accessed December 1, 2015].
88. Lim, Y. A., Mei, M. C., Kusumoto, I. T., Miyashiro, H., Hattori, M., Gupta, M. P., et al. (1997). HIV-1 reverse transcriptase inhibitory principles from Chamaesyce hyssopifolia. Phytother. Res. 11, 22-27. doi: 10.1002/(SICI)1099-1573(199702)11:1<22::AID-PTR951>3.0.CO;2-3.
89. Lin, Y.-M., Anderson, H., Flavin, M. T., Pai, Y.-H. S., Mata-Greenwood, E., Pengsuparp, T., et al. (1997). In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J. Nat. Prod. 60, 884-888. doi: 10.1021/np9700275.
90. Lindl, K. A., Marks, D. R., Kolson, D. L., and Jordan-Sciutto, K. L. (2010). HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J. Neuroimmune Pharmacol. 5, 294-309. doi: 10.1007/s11481-010-9205-z.
91. Liu, J.-S., and Li, L. (1995). Kadsulignans L-N, three dibenzocyclooctadiene lignans from Kadsura coccinea. Phytochemistry 38, 241-245. doi: 10.1016/0031-9422(94)00557-A.
92. Loya, S., Rudi, A., Kashman, Y., and Hizi, A. (1999). Polycitone A, a novel and potent general inhibitor of retroviral reverse transcriptases and cellular DNA polymerases. Biochem. J. 344, 85-92. doi: 10.1042/bj3440085.
93. Lu, W. (2013). Clinicaltrials.gov, 'Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-Responders (CACTrip12)'. Available at: Clinicaltrials.gov [accessed December 1, 2015].
94. Lüscher-Mattli, M. (2000). Polyanions-a lost chance in the fight against HIV and other virus diseases? Antivir. Chem. Chemother. 11, 249-259. doi: 10.1177/095632020001100401.
95. Mahmood, N., Piacente, S., Burke, A., Khan, A. I., and Pizza, C. (1997). Constituents of Cuscuto reflexa are anti-HIV Agents. Antivir. Chem. Chemother. 8, 70-74. doi: 10.1177/095632029700800108.
96. Malan-Muller, S., Hemmings, S. M., Spies, G., Kidd, M., Fennema-Notestine, C., and Seedat, S. (2013). Shorter telomere length-a potential susceptibility factor for HIV-associated neurocognitive impairments in South African women [corrected]. PLoS ONE 8:e58351. doi: 10.1371/journal.pone.0058351PONE-D-12-29635.
97. Mann, D. A., and Frankel, A. D. (1991). Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J. 10, 1733-1739.
98. Martin-Ruiz, C., Dickinson, H. O., Keys, B., Rowan, E., Kenny, R. A., and Von Zglinicki, T. (2006). Telomere length predicts poststroke mortality, dementia, and cognitive decline. Ann. Neurol. 60, 174-180. doi: 10.1002/ana.20869.
99. McArthur, J. C., Haughey, N., Gartner, S., Conant, K., Pardo, C., Nath, A., et al. (2003). Human immunodeficiency virus-associated dementia: an evolving disease. J. Neurovirol. 9, 205-221. doi: 10.1080/135502803901941094J811MK1R26FL3NR.
100. McArthur, J. C., Mcdermott, M. P., Mcclernon, D., St Hillaire, C., Conant, K., Marder, K., et al. (2004). Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch. Neurol. 61, 1687-1696. doi: 10.1001/archneur.61.11.1687.
101. McArthur, J. C., Steiner, J., Sacktor, N., and Nath, A. (2010). Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann. Neurol. 67, 699-714. doi: 10.1002/ana.22053.
102. McCormick, J. L., Mckee, T. C., Cardellina, J. H., and Boyd, M. R. (1996). HIV inhibitory natural products. 26. Quinoline alkaloids from Euodia roxburghiana. J. Nat. Prod. 59, 469-471. doi: 10.1021/np960250m.
103. Meragelman, K. M., Mckee, T. C., and Boyd, M. R. (2001). Anti-HIV prenylated flavonoids from Monotes africanus1. J. Nat. Prod. 64, 546-548. doi: 10.1021/np0005457.
104. Min, B. S., Jung, H. J., Lee, J. S., Kim, Y. H., Bok, S. H., Ma, C. M., et al. (1999). Inhibitory effect of triterpenes from Crataegus pinatifida on HIV-I protease. Planta Med. 65, 374-375. doi: 10.1055/s-2006-960792.
105. Min, B. S., Miyashiro, H., and Hattori, M. (2002). Inhibitory effects of quinones on RNase H activity associated with HIV-1 reverse transcriptase. Phytother. Res. 16(Suppl. 1), S57-S62. doi: 10.1002/ptr.808.
106. Mishra, L. C., Singh, B. B., and Dagenais, S. (2000). Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern. Med. Rev. 5, 334-346.
107. Mohri, H., Perelson, A. S., Tung, K., Ribeiro, R. M., Ramratnam, B., Markowitz, M., et al. (2001). Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J. Exp. Med. 194, 1277-1288. doi: 10.1084/jem.194.9.1277.
108. Molto, J. (2010). Clinicaltrials.gov, 'Drug Interactions Between Echinacea Purpurea and Darunavir/Ritonavir'. Available at: Clinicaltrials.gov [accessed December 1, 2015].
109. Munoz-Moreno, J. A., Fumaz, C. R., Ferrer, M. J., Prats, A., Negredo, E., Garolera, M., et al. (2008). Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res. Hum. Retrovir. 24, 1301-1307. doi: 10.1089/aid.2007.0310.
110. Murray, M. T., and Pizzorno, J. E. (1999). Textbook of Natural Medicine. London: Churchill Livingstone.
111. Murray, S. M., Down, C. M., Boulware, D. R., Stauffer, W. M., Cavert, W. P., Schacker, T. W., et al. (2010). Reduction of immune activation with chloroquine therapy during chronic HIV infection. J. Virol. 84, 12082-12086. doi: 10.1128/JVI.01466-10.
112. Nair, M. P. N., Saiyed, Z. M., Nair, N., Gandhi, N. H., Rodriguez, J. W., Boukli, N., et al. (2009). Methamphetamine enhances HIV-1 infectivity in monocyte derived dendritic cells. J. Neuroimmune Pharmacol. 4, 129-139. doi: 10.1007/s11481-008-9128-0.
113. Nair, M. P. N., Schwartz, S. A., Mahajan, S. D., Tsiao, C., Chawda, R. P., Whitney, R., et al. (2004). Drug abuse and neuropathogenesis of HIV infection: role of DC-SIGN and IDO. J. Neuroimmunol. 157, 56-60. doi: 10.1016/j.jneuroim.2004.08.040.
114. Nath, A., Schiess, N., Venkatesan, A., Rumbaugh, J., Sacktor, N., and Mcarthur, J. (2008). Evolution of HIV dementia with HIV infection. Int. Rev. Psychiatry 20, 25-31. doi: 10.1080/09540260701861930.
115. Nottet, H. S., and Gendelman, H. E. (1995). Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Immunol. Today 16, 441-448. doi: 10.1016/0167-5699(95)80022-0.
116. Ogata, T., Higuchi, H., Mochida, S., Matsumoto, H., Kato, A., Endo, T., et al. (1992). HIV-1 reverse transcriptase inhibitor from Phyllanthus niruri. AIDS Res. Hum. Retrovir. 8, 1937-1944. doi: 10.1089/aid.1992.8.1937.
117. Ohtake, N., Nakai, Y., Yamamoto, M., Sakakibara, I., Takeda, S., Amagaya, S., et al. (2004). Separation and isolation methods for analysis of the active principles of Sho-saiko-to (SST) oriental medicine. J. Chromatogr. B 812, 135-148. doi: 10.1016/j.jchromb.2004.06.051.
118. Orhan, D. D., Ozcelik, B., Ozgen, S., and Ergun, F. (2010). Antibacterial, antifungal, and antiviral activities of some flavonoids. Microbiol. Res. 165, 496-504. doi: 10.1016/j.micres.2009.09.002.
119. Panossian, L. A., Porter, V. R., Valenzuela, H. F., Zhu, X., Reback, E., Masterman, D., et al. (2003). Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol. Aging 24, 77-84. doi: 10.1016/S0197-4580(02)00043-X.
120. Park, J. C., Hur, J. M., Park, J. G., Hatano, T., Yoshida, T., Miyashiro, H., et al. (2002). Inhibitory effects of Korean medicinal plants and camelliatannin H from Camellia japonica on human immunodeficiency virus type 1 protease. Phytother. Res. 16, 422-426. doi: 10.1002/ptr.919.
121. Pathai, S., Lawn, S. D., Gilbert, C. E., Mcguinness, D., Mcglynn, L., Weiss, H. A., et al. (2013). Accelerated biological ageing in HIV-infected individuals in South Africa: a case-control study. AIDS 27, 2375-2384. doi: 10.1097/QAD.0b013e328363bf7f.
122. Paul, R., Flanigan, T. P., Tashima, K., Cohen, R., Lawrence, J., Alt, E., et al. (2005). Apathy correlates with cognitive function but not CD4 status in patients with human immunodeficiency virus. J. Neuropsychiatry Clin. Neurosci. 17, 114-118. doi: 10.1176/jnp.17.1.114.
123. Petrovas, C., Casazza, J. P., Brenchley, J. M., Price, D. A., Gostick, E., Adams, W. C., et al. (2006). PD-1 is a regulator of virus-specific CD8(+) T cell survival in HIV infection. J. Exp. Med. 203, 2281-2292. doi: 10.1084/jem.20061496.
124. Piconi, S., Parisotto, S., Rizzardini, G., Passerini, S., Terzi, R., Argenteri, B., et al. (2011). Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 118, 3263-3272. doi: 10.1182/blood-2011-01-329060.
125. Ptak, R. G. (2002). HIV-1 regulatory proteins: targets for novel drug development. Expert Opin. Investig. Drugs 11, 1099-1115. doi: 10.1517/13543784.11.8.1099.
126. Rambaut, A., Robertson, D. L., Pybus, O. G., Peeters, M., and Holmes, E. C. (2001). Human immunodeficiency virus: phylogeny and the origin of HIV-1. Nature 410, 1047-1048. doi: 10.1038/35074179.
127. Reddy, P. V., Pilakka-Kanthikeel, S., Saxena, S. K., Saiyed, Z., and Nair, M. P. (2012). Interactive effects of morphine on HIV infection: role in HIV-associated neurocognitive disorder. AIDS Res. Treat. 2012:953678. doi: 10.1155/2012/953678.
128. Resh, M. D. (2005). Intracellular trafficking of HIV-1 Gag: how Gag interacts with cell membranes and makes viral particles. AIDS Rev. 7, 84-91.
129. Rimando, A. M., Pezzuto, J. M., Farnsworth, N. R., Santisuk, T., Reutrakul, V., and Kawanishi, K. (1994). New lignans from Anogeissus acuminata with HIV-1 reverse transcriptase inhibitory activity. J. Nat. Prod. 57, 896-904. doi: 10.1021/np50109a004.
130. Robertson, K. R., Smurzynski, M., Parsons, T. D., Wu, K., Bosch, R. J., Wu, J., et al. (2007). The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21, 1915-1921. doi: 10.1097/QAD.0b013e32828e4e2700002030-200709120-00011.
131. Rodriguez, B., Sethi, A. K., Cheruvu, V. K., Mackay, W., Bosch, R. J., Kitahata, M., et al. (2006). Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296, 1498-1506. doi: 10.1001/jama.296.12.1498.
132. Roth, G. N., Chandra, A., and Nair, M. G. (1998). Novel bioactivities of Curcuma longa constituents. J. Nat. Prod. 61, 542-545. doi: 10.1021/np970459f.
133. Roy, U., Atluri, V. S., Agudelo, M., Yndart, A., Huang, Z., and Nair, M. (2015). DJ1 expression downregulates in neuroblastoma cells (SK-N-MC) chronically exposed to HIV-1 and cocaine. Front. Microbiol. 6:749. doi: 10.3389/fmicb.2015.00749.
134. Rukachaisirikul, V., Pailee, P., Hiranrat, A., Tuchinda, P., Yoosook, C., Kasisit, J., et al. (2003). Anti-HIV-1 protostane triterpenes and digeranylbenzophenone from trunk bark and stems of Garcinia speciosa. Planta Med. 69, 1141-1146. doi: 10.1055/s-2003-818006.
135. Sacktor, N., Lyles, R. H., Skolasky, R., Kleeberger, C., Selnes, O. A., Miller, E. N., et al. (2001). HIV-associated neurologic disease incidence changes: multicenter AIDS cohort study, 1990-1998. Neurology 56, 257-260. doi: 10.1212/WNL.56.2.257.
136. Sacktor, N., Mcdermott, M., Marder, K., Schifitto, G., Selnes, O., Mcarthur, J., et al. (2002). HIV-associated cognitive impairment before and after the advent of combination therapy. J. Neurovirol. 8, 136-142. doi: 10.1080/13550280290049615.
137. Sagar, V., Pilakka-Kanthikeel, S., Atluri, V. S. R., Ding, H., Arias, A. Y., Jayant, R. D., et al. (2015). Therapeutical neurotargeting via magnetic nanocarrier: implications to opiate-induced neuropathogenesis and NeuroAIDS. J. Biomed. Nanotechnol. 11, 1722-1733. doi: 10.1166/jbn.2015.2108.
138. Sakurai, N., Wu, J. H., Sashida, Y., Mimaki, Y., Nikaido, T., Koike, K., et al. (2004). Anti-AIDS agents. Part 57: actein, an anti-HIV principle from the rhizome of Cimicifuga racemosa (black cohosh), and the anti-HIV activity of related saponins. Bioorg Med. Chem. Lett. 14, 1329-1332. doi: 10.1016/j.bmcl.2003.12.035S0960894X03013222.
139. Samikkannu, T., Ranjith, D., Rao, K. V., Atluri, V. S., Pimentel, E., El-Hage, N., et al. (2015a). HIV-1 gp120 and morphine induced oxidative stress: role in cell cycle regulation. Front. Microbiol. 6:614. doi: 10.3389/fmicb.2015.00614.
140. Samikkannu, T., Rao, K. V., Salam, A. A., Atluri, V. S., Kaftanovskaya, E. M., Agudelo, M., et al. (2015b). HIV subtypes B and C gp120 and methamphetamine interaction: dopaminergic system implicates differential neuronal toxicity. Sci. Rep. 5:11130. doi: 10.1038/srep11130.
141. Samikkannu, T., Rao, K. K., Gandhi, N., Saxena, S., and Nair, M. N. (2010). Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: implications for neuroAIDS. J. Neurovirol. 16, 255-263. doi: 10.3109/13550284.2010.497809.
142. Sankar, S. R., Manivasagam, T., Krishnamurti, A., and Ramanathan, M. (2007). The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: an analysis of behavioral and biochemical variables. Cell Mol. Biol. Lett. 12, 473-481. doi: 10.2478/s11658-007-0015-0.
143. Saxena, S. K., Tiwari, S., and Nair, M. P. (2012). A global perspective on HIV/AIDS. Science 337:798. doi: 10.1126/science.337.6096.798.
144. Schader, S. M., and Wainberg, M. A. (2011). Insights into HIV-1 pathogenesis through drug discovery: 30 years of basic research and concerns for the future. HIV AIDS Rev. 10, 91-98. doi: 10.1016/j.hivar.2011.09.003.
145. Schulz, V. (2006). Safety of St. John's Wort extract compared to synthetic antidepressants. Phytomedicine 13, 199-204. doi: 10.1016/j.phymed.2005.07.005.
146. Sebit, M. B., Chandiwana, S. K., Latif, A. S., Gomo, E., Acuda, S. W., Makoni, F., et al. (2000). Quality of life evaluation in patients with HIV-I infection: the impact of traditional medicine in Zimbabwe. Cent. Afr. J. Med. 46, 208-213.
147. Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., et al. (2012). Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc. Natl. Acad. Sci. U.S.A. 109, 3510-3515.
148. Sharer, L. R. (1992). Pathology of HIV-1 infection of the central nervous system. A review. J. Neuropathol. Exp. Neurol. 51, 3-11. doi: 10.1097/00005072-199201000-00002.
149. Short, R. V. (2006). New ways of preventing HIV infection: thinking simply, simply thinking. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361, 811-820. doi: 10.1098/rstb.2005.1781.
150. Simioni, S., Cavassini, M., Annoni, J. M., Rimbault Abraham, A., Bourquin, I., Schiffer, V., et al. (2010). Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24, 1243-1250. doi: 10.1097/QAD.0b013e3283354a7b.
151. Soontornniyomkij, V., Moore, D. J., Gouaux, B., Soontornniyomkij, B., Tatro, E. T., Umlauf, A., et al. (2012). Cerebral beta-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE epsilon4 carriers. AIDS 26, 2327-2335. doi: 10.1097/QAD.0b013e32835a117c.
152. Sun, Y., Huang, P. L., Li, J. J., Huang, Y. Q., Zhang, L., Huang, P. L., et al. (2001). Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi's sarcoma-associated virus. Biochem. Biophys. Res. Commun. 287, 983-994. doi: 10.1006/bbrc.2001.5689.
153. Tan, G. T., Pezzuto, J. M., Kinghorn, A. D., and Hughes, S. H. (1991). Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. J. Nat. Prod. 54, 143-154. doi: 10.1021/np50073a012.
154. Tozzi, V., Balestra, P., Galgani, S., Narciso, P., Ferri, F., Sebastiani, G., et al. (1999). Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 13, 1889-1897. doi: 10.1097/00002030-199910010-00011.
155. Uchiumi, F., Hatano, T., Ito, H., Yoshida, T., and Tanuma, S. (2003). Transcriptional suppression of the HIV promoter by natural compounds. Antiviral Res. 58, 89-98. doi: 10.1016/S0166-3542(02)00186-9.
156. Uchiumi, F., Maruta, H., Inoue, J., Yamamoto, T., and Tanuma, S. (1996). Inhibitory effect of tannic acid on human immunodeficiency virus promoter activity induced by 12-O-tetra decanoylphorbol-13-acetate in Jurkat T-cells. Biochem. Biophys. Res. Commun. 220, 411-417. doi: 10.1006/bbrc.1996.0419.
157. UNAIDS (2010). UNAIDS Report on the Global AIDS Epidemic 2010. Geneva: UNAIDS.
158. UNAIDS (2011). World AIDS Day Report 2011. Geneva: UNAIDS.
159. Valdes, A. M., Deary, I. J., Gardner, J., Kimura, M., Lu, X., Spector, T. D., et al. (2008). Leukocyte telomere length is associated with cognitive performance in healthy women. Neurobiol. Aging 31, 986-992. doi: 10.1016/j.neurobiolaging.2008.07.012.
160. Valenti, W. M. (2001). HAART is cost-effective and improves outcomes. AIDS Read. 11, 260-262.
161. Vermani, K., and Garg, S. (2002). Herbal medicines for sexually transmitted diseases and AIDS. J. Ethnopharmacol. 80, 49-66. doi: 10.1016/S0378-8741(02)00009-0.
162. Vitiello, B., Goodkin, K., Ashtana, D., Shapshak, P., Atkinson, J. H., Heseltine, P. N., et al. (2007). HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people. AIDS 21, 1415-1422. doi: 10.1097/QAD.0b013e328220e71a00002030-200707110-00004.
163. Vlietinck, A. J., De Bruyne, T., Apers, S., and Pieters, L. A. (1998). Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Med. 64, 97-109. doi: 10.1055/s-2006-957384.
164. von Zglinicki, T., Serra, V., Lorenz, M., Saretzki, G., Lenzen-Grossimlighaus, R., Gessner, R., et al. (2000). Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor? Lab. Invest. 80, 1739-1747. doi: 10.1038/labinvest.3780184.
165. Wang, J. (2009a). Clinicaltrials.gov, 'Clinical Trials on the Effect of Immunity 1 (Fuzheng 1) On Immune Reconstitution of HIV Patients'. Available at: Clinicaltrials.gov [accessed December 1, 2015].
166. Wang, J. (2009b). Clinicaltrials.gov, 'Research on Effect of Traditional Chinese Medicine (TCM) on Immune Reconstitution of HIV/AIDS Patients After Highly Active Antiretroviral Therapy (HAART)'. Available at: Clinicaltrials.gov [accessed December 1, 2015].
167. Wang, J. (2009c). Clinicaltrials.gov, 'The Effect of Combination of Traditional Chinese Medicine (TCM) and Highly Active Antiretroviral Therapy (HAART) on Immune Reconstitution of HIV/AIDS Patients'. Available at: Clinicaltrials.gov [accessed December 1, 2015].
168. Wang, J. N., Hou, C. Y., Liu, Y. L., Lin, L. Z., Gil, R. R., and Cordell, G. A. (1994). Swertifrancheside, an HIV-reverse transcriptase inhibitor and the first flavone-xanthone dimer, from Swertia franchetiana. J. Nat. Prod. 57, 211-217. doi: 10.1021/np50104a003.
169. Wang, Q., Ding, Z.-H., Liu, J.-K., and Zheng, Y.-T. (2004). Xanthohumol, a novel anti-HIV-1 agent purified from Hops Humulus lupulus. Antiviral Res. 64, 189-194. doi: 10.1016/j.antiviral.2004.08.005.
170. Wayengera, M. (2011). Targeting persistent HIV infection: where and how, if possible? HIV AIDS Rev. 10, 1-8. doi: 10.1016/j.hivar.2011.01.002.
171. Witvrouw, M., and De Clercq, E. (1997). Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen. Pharmacol. 29, 497-511. doi: 10.1016/S0306-3623(96)00563-0.
172. World Health Organization [WHO] (1989a). In vitro screening of traditional medicines for anti-HIV activity: memorandum from a WHO meeting. Bull. World Health Organ. 67, 613-618.
173. World Health Organization [WHO] (1989b). Report of a WHO Informal Consultation on Traditional Medicine and AIDS: In Vitro Screening for Anti-HIV Activity, Geneva, 6-8 February 1989. Geneva: World Health Organization.
174. World Health Organization [WHO] (2002). WHO Traditional Medicine Strategy 2002-2005. Geneva: World Health Organization, 1-61.
175. Xu, H. X., Wan, M., Dong, H., But, P. P., and Foo, L. Y. (2000). Inhibitory activity of flavonoids and tannins against HIV-1 protease. Biol. Pharm. Bull. 23, 1072-1076. doi: 10.1248/bpb.23.1072.
176. Xu, H.-X., Zeng, F.-Q., Wan, M., and Sim, K.-Y. (1996). Anti-HIV triterpene acids from Geum japonicum. J. Nat. Prod. 59, 643-645. doi: 10.1021/np960165e.
177. Xu, J., and Ikezu, T. (2009). The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J. Neuroimmune Pharmacol. 4, 200-212. doi: 10.1007/s11481-008-9136-0.
178. Yaffe, K., Lindquist, K., Kluse, M., Cawthon, R., Harris, T., Hsueh, W.-C., et al. (2009). Telomere length and cognitive function in community-dwelling elders: findings from the Health ABC Study. Neurobiol. Aging 32, 2055-2060. doi: 10.1016/j.neurobiolaging.2009.12.006.
179. Yamaguchi, K., Honda, M., Ikigai, H., Hara, Y., and Shimamura, T. (2002). Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res. 53, 19-34. doi: 10.1016/S0166-3542(01)00189-9.
180. Yao-Haur, K., and Li-Ming Yang, K. (1997). Antitumour and anti-AIDS triterpenes from Celastrus hindsii. Phytochemistry 44, 1275-1281. doi: 10.1016/S0031-9422(96)00719-4.
181. Yu, D., Suzuki, M., Xie, L., Morris-Natschke, S. L., and Lee, K.-H. (2003). Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med. Res. Rev. 23, 322-345. doi: 10.1002/med.10034.
182. Zanet, D. L., Thorne, A., Singer, J., Maan, E. J., Sattha, B., Le Campion, A., et al. (2012). Association between short leukocyte telomere length and HIV infection in a cohort study: no evidence of a relationship with antiretroviral therapy. Clin. Infect. Dis. 58, 1322-1332. doi: 10.1093/cid/ciu051.
183. Zhou, P., Takaishi, Y., Duan, H., Chen, B., Honda, G., Itoh, M., et al. (2000). Coumarins and bicoumarin from Ferula sumbul: anti-HIV activity and inhibition of cytokine release. Phytochemistry 53, 689-697. doi: 10.1016/S0031-9422(99)00554-3.
184. Zou, W., Kim, B. O., Zhou, B. Y., Liu, Y., Messing, A., and He, J. J. (2007). Protection against human immunodeficiency virus type 1 Tat neurotoxicity by Ginkgo biloba extract EGb 761 involving glial fibrillary acidic protein. Am. J. Pathol. 171, 1923-1935. doi: 10.2353/ajpath.2007.070333.